These mechanisms may also explain why sodium-glucose cotransporter 2 (SGLT2) inhibitors effectively improve HF symptoms even in nondiabetic patients [29, 30]: SGLT2 inhibitors suppress acute hyperglycemia, decrease oxidative stress [31], and improve cardiac mitochondrial function, leading to left ventricular function improvement [32]. Here, SLC5A2 is linked to Hyperglycemia.